Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068788A1
Heterocyclic amides as btk inhibitors
CA2723237A1
Substituted amides, method of making, and use as btk inhibitors
EP2252617A1
6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
ZA200708108B
Certain substituted amides, method of making, and method of use thereof
WO2008033858A2
Kinase inhibitors, and methods of using and identifying kinase inhibitors
WO2008033834A1
Pyrimidines derivatives and their use as kinase inhibitors
BRPI0716918A2
Compound, pharmaceutical composition, packaged pharmaceutical composition, method of treating a patient who has a disease responsible for btk activity, method of treating a patient who has a clear alternative disease, customs disease increasing sensitivity of cancer cells to chemotherapy, method of reducing medication error and improving therapeutic patient disease by being treated to a disease responsible for btk métir de médid activity inhibition btk in a sample, method of inhibiting b-cell activity
US2008153834A1
Certain substituted amides, method of making, and method of use thereof
US2006270702A1
Certain substituted ureas, as modulators of kinase activity
CN101223141A
Certain substituted amides, method of making, and method of use thereof
WO2006076592A1
1,3 substituted diaryl ureas as modulators of kinase activity
CN101163691A
1,3-diaryl substituted ureas as modulators of kinase activity
CN101124227A
Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
SG159549A1
Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US7259164B2
Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
